Boston Partners Has $27.33 Million Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Boston Partners lifted its position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 1.3% in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 1,291,868 shares of the biopharmaceutical company's stock after buying an additional 16,601 shares during the quarter. Boston Partners owned about 1.08% of Catalyst Pharmaceuticals worth $27,325,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently modified their holdings of the company. Steward Partners Investment Advisory LLC acquired a new stake in Catalyst Pharmaceuticals during the fourth quarter worth approximately $27,000. Farther Finance Advisors LLC grew its holdings in shares of Catalyst Pharmaceuticals by 125.1% during the 4th quarter. Farther Finance Advisors LLC now owns 2,690 shares of the biopharmaceutical company's stock worth $56,000 after purchasing an additional 1,495 shares in the last quarter. Larson Financial Group LLC increased its position in shares of Catalyst Pharmaceuticals by 27,218.2% in the third quarter. Larson Financial Group LLC now owns 3,005 shares of the biopharmaceutical company's stock worth $60,000 after purchasing an additional 2,994 shares during the period. Wilmington Savings Fund Society FSB bought a new position in shares of Catalyst Pharmaceuticals in the fourth quarter worth $65,000. Finally, KBC Group NV raised its stake in Catalyst Pharmaceuticals by 48.8% in the fourth quarter. KBC Group NV now owns 4,699 shares of the biopharmaceutical company's stock valued at $98,000 after purchasing an additional 1,542 shares in the last quarter. Institutional investors and hedge funds own 79.22% of the company's stock.

Remove Ads

Catalyst Pharmaceuticals Stock Up 6.2 %

Catalyst Pharmaceuticals stock traded up $1.51 during trading hours on Monday, hitting $25.74. The stock had a trading volume of 3,104,161 shares, compared to its average volume of 1,063,453. The business's 50 day simple moving average is $22.39 and its 200-day simple moving average is $21.63. Catalyst Pharmaceuticals, Inc. has a one year low of $14.47 and a one year high of $26.14. The stock has a market cap of $3.13 billion, a price-to-earnings ratio of 21.81, a P/E/G ratio of 3.31 and a beta of 0.84.

Insider Transactions at Catalyst Pharmaceuticals

In other news, insider Gary Ingenito sold 44,904 shares of the stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $22.09, for a total value of $991,929.36. Following the completion of the sale, the insider now owns 68,873 shares of the company's stock, valued at approximately $1,521,404.57. This represents a 39.47 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Brian Elsbernd sold 62,975 shares of Catalyst Pharmaceuticals stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $22.98, for a total value of $1,447,165.50. Following the completion of the transaction, the insider now directly owns 188,564 shares in the company, valued at approximately $4,333,200.72. This represents a 25.04 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 11.00% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

Several research firms have commented on CPRX. Baird R W raised shares of Catalyst Pharmaceuticals to a "strong-buy" rating in a report on Monday, February 3rd. Robert W. Baird lifted their price objective on shares of Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the company an "outperform" rating in a research note on Monday, March 3rd. StockNews.com upgraded Catalyst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Friday, February 28th. Bank of America reaffirmed a "buy" rating and issued a $30.00 target price on shares of Catalyst Pharmaceuticals in a report on Thursday, January 9th. Finally, Stephens restated an "overweight" rating and set a $33.00 price objective on shares of Catalyst Pharmaceuticals in a research report on Thursday, February 27th. Seven analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, Catalyst Pharmaceuticals has an average rating of "Buy" and a consensus target price of $32.29.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.